Living To 120 Will Be Normal Within 20 Years Thanks To The Longevity Revolution

TL;DR

Longevity technologies may normalize living to 120 within 20 years.

Transcript

But effectively what we've now started to see is that those drugs have gone from uh people helping with helping people with their type 2 diabetes um going from from that to saying okay well actually these drugs now have been analyzed because they've been in market for a long time realizing that they are uh cardior protective so they help at the met... Read More

Key Insights

• GLP-1 agonists, initially for diabetes, are now seen as potential therapies for cardiovascular and cognitive health, marking a shift from disease management to prevention.
• The longevity industry is divided into three phases: current technologies (1.0), emerging therapies for disease prevention (2.0), and future revolutionary technologies (3.0).
• Phil Newman founded Longevity.Technology to consolidate the industry, aiming to make it accessible for investors, policymakers, and innovators.
• The longevity market is structured into 10 levels, from lifestyle management and diagnostics to systemic age reversal and consciousness preservation.
• Investment in the longevity sector has grown significantly, reaching $8.4 billion in 2024, but there is a need for more mid-stage funding.
• Regulatory environments are evolving to support the use of aging biomarkers, which may accelerate the approval of longevity therapies.
• Longevity escape velocity, the concept of living indefinitely with minimal aging, is seen as achievable within 50 years, with systemic age reversal being a key milestone.
• The $110 million XPRIZE is driving innovation in the longevity space, with a focus on both high-tech solutions and community-based approaches.

Questions & Answers

Q: What is the significance of GLP-1 agonists in the longevity industry?

GLP-1 agonists, initially developed for type 2 diabetes, have shown potential for cardiovascular protection and cognitive health improvement. This marks a significant shift from traditional disease management to prevention, as these drugs are now being used to prevent aging-related diseases. The success of GLP-1 agonists has also attracted significant investment and interest from pharmaceutical companies, indicating a broader industry trend towards preventive therapies.

Q: How is the longevity market structured according to Phil Newman?

Phil Newman structures the longevity market into three phases: Longevity 1.0, which includes current technologies like wearables and diagnostics; Longevity 2.0, focusing on emerging therapies for disease prevention; and Longevity 3.0, which involves revolutionary technologies like partial cellular reprogramming for systemic age reversal. This structured approach helps investors and companies navigate the complex industry landscape and identify areas of interest and opportunity.

Q: What are the 10 levels of longevity described by Phil Newman?

The 10 levels of longevity range from lifestyle management and consumer diagnostics to longevity biohacking and clinics. They progress to aging disease management, prevention, and targeted age reversal at an organ level. The higher levels include systemic age reversal, organism maintenance through organ replacement, and ultimately, consciousness preservation through advanced technologies. This framework helps categorize the industry's diverse approaches and innovations.

Q: What role does investment play in the longevity industry?

Investment is crucial for the growth of the longevity industry, with significant funds directed towards later-stage companies that demonstrate strong clinical evidence. However, there is a gap in mid-stage funding, which Phil Newman aims to address through data-driven investment tools. The investment landscape is diverse, with contributions from venture capital, family offices, and public markets, but more dedicated longevity-focused funds are needed to fully realize the industry's potential.

Q: How are regulatory changes impacting the longevity industry?

Regulatory changes are increasingly supporting the use of aging biomarkers, which could accelerate the approval of longevity therapies. Governments recognize the economic and social benefits of keeping aging populations healthy and productive. Initiatives like Montana's right-to-try laws for experimental therapies indicate a shift towards more accessible and innovative healthcare solutions, which could significantly impact the development and deployment of longevity technologies.

Q: What is longevity escape velocity and how soon could it be achieved?

Longevity escape velocity is the concept of living indefinitely by staying healthy enough to benefit from future medical advancements. Phil Newman believes it is achievable within 50 years, with systemic age reversal being a key milestone. The concept involves not only biological advancements but also complementary technologies like AI and quantum computing, which could accelerate progress towards this goal. However, the exact timeline remains uncertain and will likely become clear only in hindsight.

Q: What is the impact of the XPRIZE on the longevity industry?

The $110 million XPRIZE is a significant driver of innovation in the longevity industry, encouraging diverse approaches to extending healthy lifespan. The competition includes both high-tech solutions and community-based approaches, highlighting the multifaceted nature of longevity research. The XPRIZE aims to accelerate the development of groundbreaking technologies, with the potential to bring transformative therapies to market and advance the industry's goals significantly.

Q: What technologies are expected to reach the market in the near future?

Technologies expected to reach the market soon include therapies for sarcopenia and senescence, advancements in GLP-1 agonists, and enhanced versions of existing drugs like metformin and rapamycin. These therapies are in various stages of clinical development and are anticipated to address critical aging-related conditions. Partial cellular reprogramming, although still experimental, shows promise for reversing age at an organ level, with potential long-term implications for systemic age reversal.

Summary & Key Takeaways

• Phil Newman discusses the rapid advancements in longevity technologies, highlighting the shift from disease management to prevention, with drugs like GLP-1 agonists playing a key role. The industry is categorized into three phases, indicating a future where living to 120 could become common.

• Investment in longevity is booming, with significant funds directed towards later-stage companies. However, there's a gap in mid-stage funding, which Newman aims to address through data-driven investment tools. Regulatory changes are also supporting the industry's growth.

• The longevity market is structured into 10 levels, from current lifestyle management to future systemic age reversal. The XPRIZE is accelerating innovation, with new therapies for conditions like sarcopenia and senescence expected within five years.